GVR Report cover Intravenous Immunoglobulin Market Size, Share & Trends Report

Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Hypogammaglobulinemia, CIDP, Congenital AIDS), By Route of Administration, And Segment Forecasts, 2012 - 2022

  • Published Date: Feb, 2018
  • Base Year for Estimate: 2015
  • Report ID: 978-1-68038-800-8
  • Format: Electronic (PDF)
  • Historical Data: 2012 - 2015
  • Number of Pages: 100

Industry Insights

The global intravenous immunoglobulin market size was estimated at USD 9.09 billion in 2016 and is anticipated to grow at a CAGR of 7.1% over the forecast period. Growing geriatric population, rising prevalence of immunodeficiency diseases, increasing adoption of IVIG treatments, and rising use of off-label indications are the key drivers of the market. Rising number of patients with immunodeficiency disorders is the primary cause for the development of IVIG preparations.

U.S. intravenous immunoglobulin market

According to the W.H.O, currently, there are over 50 different Primary Immune Deficiency (PID’s) such as specific antibody deficiency, X-lined hypo-gamma-globulinemia, and others. PIDs include 176 different types of rare hereditary disorders. According to the U.S. National Library of Medicine and National Institute of Health, approximately 6 million patients are suffering from PID worldwide. Growing incidences of these diseases are expected to boost the demand for immunoglobulin therapies over the forecast period.

The demand for IVIG therapies for the treatment of acquired and primary immunodeficiency diseases is increasing as it is the most effective & the only available treatment option. Moreover, sedentary lifestyle habits, including consumption of saturated fats salt, & sugars, less physical activities, and high alcohol consumption have led to an increase in the prevalence of these diseases. Rising prevalence of lifestyle-associated disorders such as obesity & antibody deficiency disorders are the factors expected to drive the growth.

The global geriatric population base is on a rise. According to a report published by the United States Census Bureau, the number of people aged 65 and older in the U.S. was approximately 46.2 million in 2014 and is expected to reach over 98 million by 2060. Aging also weakens immune systems and consequently heightens a patient’s susceptibility towards acquiring infectious diseases. The global base of geriatric population is expected to grow over the next few years is expected to serve this industry as a high impact rendering driver.

Application Insights

Hypogammaglobulinemia dominated the application segment at 21.1% in 2014. This can be attributed to the owing to increasing incidences of primary immunodeficiency diseases (PID) worldwide. It is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs). As per the CDC in 2012, the incidence rate of hypogammaglobulinemia across the globe was around 2 per 100,000 populations every year and is expected to rise in the near future. Increasing incidence of immunodeficiency disorders coupled with the high adoption of IVIG therapies is expected to drive the segment growth in the near future.

Chronic Inflammatory demyelinating polyneuropathy (CIDP) segment held the second-largest share of the IVIG market on the basis of application. It is usually found in patients with diabetes mellitus. The treatment of CIPD involves the use of immunosuppressive drugs, steroids, and plasmapheresis. IVIG is an effective and long-lasting alternative to these methods. The associated benefits such as safety, minimally invasive and user-friendly treatment option are the factors contributing towards the development of the industry.

Immunodeficiency diseases accounted for the third-largest share of the industry owing to the increasing incidence of primary and acquired immunodeficiency diseases (PID & AID). PID & AID need to be treated with IV antibiotics to clear the infections. IVIG replacement therapy is the best available alternative for the treatment of immunodeficiency diseases. Hence the business is expected to show steady growth in the coming years.

Kawasaki disease segment is expected to exhibit lucrative growth owing to rising incidences of Kawasaki disease in children and rising demand for IVIG procedures for its treatment. The alternative for IVIG therapy is steroids which have more side effects; hence the penetration of IVIG therapies for the treatment of Kawasaki disease is expected to grow in the coming years. Moreover, factors such as increasing patient awareness levels and rising incidence of antibody deficiency diseases, and are expected to boost the demand for IVIG therapy consequentially driving the growth of this segment.

Route of Administration Insights

Intravenous administration accounted for the largest revenue share in 2014, of the route of administration segment. The substantial share is a direct consequence of high usage of intravenous immunoglobulins in a wide range of immunology applications. Intravenous administration of IVIGs is the primary line of treatment for immunodeficiency illness.

Moreover, increasing number of intravenous product approvals and clinical trials for new clinical applications is anticipated to provide potential growth opportunities for the industry. Increasing healthcare expenditure and growing awareness pertaining to autoimmune diseases are also anticipated to further facilitate the growth of this segment.

Global intravenous immunoglobulin market

Subcutaneous administration is expected to grow at an exponential rate of 9.8% over the forecast period. Increasing incorporation of subcutaneous IGs in the treatment of PIDs is anticipated to provide growth potential to this segment. This can be attributed to potential advantages associated with subcutaneous administration such as quick response and fewer side effects.

The segment growth is also driven by key contributing factors such as increasing usage and preference of subcutaneous immunoglobulin in home based self-infusion immunotherapy. The extensive product pipeline of subcutaneously administered IVIGs is anticipated to further contribute towards the growth of this segment.

Regional Insights

North America dominated the overall market in terms of revenue in 2014 at 47.7%. Increasing level of awareness pertaining to products involved in the treatment of immunodeficiency diseases, rising inclination of clinicians towards these therapies, and growing healthcare expenditure are the key factors contributing towards the market growth.

Changing lifestyle and rising geriatric population prone to chronic diseases are some of the factors contributing to the growth of this industry. In addition, increasing incidences of PID is expected to present this market with future growth opportunities. According to the American Autoimmune Related Disease Association Inc. (AARDA), near about 50 million Americans were suffered from autoimmune diseases in the year 2012 and the number is expected to grow over the forecast period.

Asia Pacific is anticipated to exhibit lucrative growth over the forecast period as a consequence of increasing awareness and potential opportunities for adoption of immunoglobulin based therapies for the treatment of primary immune deficiencies coupled with growing geriatric population.

Other factors contributing to the development of this business are emerging economies, growing healthcare spending, and rapidly growing immunoglobulin market. In addition, rising incidences of immune disorders, awareness levels pertaining to intravenous & subcutaneous immunoglobulin therapies, and improving healthcare facilities is anticipating further growth in the near future.

Intravenous Immunoglobulin Market Share Insights

The global immunoglobulin industry is consolidated in nature and a limited number of players have a high level of dominance over the global revenue share. The key players are Biotest AG, Baxter International Inc., Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc., Kedrion Biopharma, and BDI Pharma Inc.

Market leaders are involved in extensive R&D for the development of cost-effective and sensitive immunoglobulin therapies with lesser side effects. For instance, In January 2015, Grifols SA’s purification plant received FDA approval for the production of intravenous immunoglobulin (IVIG) 10%, plasma protein marketed under brands Gamunex and Flebogamma, thereby expanding its product portfolio and gaining more market share.

This industry is experiencing a significant boost owing to growing number of FDA approvals. Owing to this a number of local and international players are investing in the IVIG business.

Market players are adopting various strategies such as mergers and acquisitions, distribution, and other collaborative agreements to gain a greater share by increasing their market penetration. For instance, in September 2015, China Biologics entered into a collaboration agreement with Xinjiang Deyuan Bioengineering Co., Ltd to source raw material required for the production of IVIG products and human albumin thereby strengthening its operational capabilities.

Report Scope



Base year for estimation


Actual estimates/Historical data

2012 - 2015

Forecast period

2016 - 2022

Market representation                                 

Revenue in USD Million and CAGR from 2015 to 2022

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, UK, Germany, Japan, China, India, Brazil, Mexico, South Africa

Report coverage      

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at global, regional, & country levels and provides an analysis of the industry trends in each of the sub-segments from 2012 to 2022. For the purpose of this study, Grand View Research has segmented the global intravenous immunoglobulin market report on the basis of application, route of administration, and region:

  • Application Outlook (Revenue, USD Million, 2012 - 2022)

    • Hypogammaglobulinemia

    • CIPD

    • Immunodeficiency diseases

    • Congenital AIDS

    • Chronic Lymphocytic Leukemia

    • Myasthenia Gravis

    • Multifocal motor neuropathy

    • ITP

    • Kawasaki disease

    • Guillain-Barre syndrome

    • Others

  • Route of Administration Outlook (Revenue, USD Million, 2012 - 2022)

    • Intravenous

    • Subcutaneous

  • Regional Outlook (Revenue, USD Million, 2012 - 2022)

    • North America

      • The U.S.

      • Canada

    • Europe

      • The U.K.

      • Germany

    • Asia Pacific

      • Japan

      • China

      • India

    • Latin America

      • Brazil

      • Mexico

    • The Middle East and Africa

      • South Africa

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.